However, our bodies take a little while to catch up
In a statement published alongside the results, Amgen said: Weight loss had not plateaued by 52 weeks, indicating the potential for further weight reduction. It added that improvements were recorded across other cardiometabolic measures, including waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP) and select lipid parameters
The secondary outcome included the impact of GLP-1 agonists on emotional eating behaviors including emotional eating scores
The treatment plan is outlined in Fig
This is the most important recommendation in this entire article
Investors should track the net sales to gross sales ratio over the next four to six quarters as payer mix evolves: if net-to-gross deteriorates faster than patient volume grows, it signals that payer-mandated step therapy requirements are limiting the addressable population more than the companys guidance implies